How should Entrectinib be dosed and monitored in patients with NTRK‑fusion solid tumors or ROS1‑positive non‑small cell lung cancer, including adjustments for hepatic impairment and precautions for CNS disorders, uncontrolled hypertension, QT prolongation, and pregnancy?

Entrectinib Dosing and Monitoring

Entrectinib should be dosed at 600 mg orally once daily in adults with ROS1-positive metastatic NSCLC or NTRK fusion-positive solid tumors, with mandatory baseline cardiac, hepatic, and QT interval assessments before initiation. 1

Indications and Patient Selection

Entrectinib is FDA-approved for two distinct populations:

• ROS1-positive metastatic NSCLC in adults (detected by FDA-approved test)
• NTRK gene fusion-positive solid tumors in adults and pediatric patients >1 month of age, where tumors are metastatic or surgical resection would cause severe morbidity, and patients have progressed on prior treatment or lack satisfactory alternatives 1

The NTRK indication carries accelerated approval status, contingent on confirmatory trial verification 2, 1.

Standard Dosing

Adults

• 600 mg orally once daily for both ROS1-positive NSCLC and NTRK fusion-positive tumors 1
• Administer with or without food (food has no clinically significant effect on absorption) 1

Pediatric Patients (NTRK fusion-positive tumors)

Age >6 months: Dose based on body surface area (BSA):

• BSA ≤0.50 m²: 300 mg/m² once daily
• BSA 0.51-0.80 m²: 200 mg once daily
• BSA 0.81-1.10 m²: 300 mg once daily
• BSA 1.11-1.50 m²: 400 mg once daily
• BSA ≥1.51 m²: 600 mg once daily

Age >1 month to ≤6 months: 250 mg/m² once daily 1

Mandatory Pre-Treatment Assessments

Before initiating entrectinib, evaluate:

1. Left ventricular ejection fraction (LVEF) - baseline echocardiogram or MUGA scan
2. Serum uric acid levels
3. QT interval and electrolytes (potassium, magnesium, calcium)
4. Liver function tests (ALT, AST, total bilirubin) 1

Hepatic Impairment Dosing

Mild hepatic impairment (total bilirubin ≤ULN with AST >ULN, or total bilirubin 1.0-1.5× ULN): No dose adjustment required 1

Moderate to severe hepatic impairment: No specific dosing recommendations available in the FDA label; entrectinib pharmacokinetics show no clinically significant differences with mild impairment only 1. Exercise extreme caution or avoid use in moderate-severe impairment given hepatotoxicity risk.

Drug Interaction Dose Modifications

With moderate CYP3A inhibitors (e.g., fluconazole, verapamil): Reduce entrectinib dose by 50% (to 300 mg once daily in adults) 1

With strong CYP3A inhibitors (e.g., clarithromycin, itraconazole, ritonavir): Reduce entrectinib dose by 75% (to 150 mg once daily in adults). Avoid concomitant use if possible 1

Strong CYP3A inducers (e.g., rifampin, phenytoin, carbamazepine): Avoid concomitant use - may significantly reduce entrectinib efficacy 1

Monitoring Schedule

Cardiac Monitoring

• Baseline LVEF before treatment initiation
• Monitor for clinical signs/symptoms of congestive heart failure (CHF) throughout treatment: dyspnea, peripheral edema, fatigue, orthopnea
• Reassess LVEF if any signs/symptoms of CHF develop
• Consider cardiac MRI or biopsy if myocarditis suspected (can occur with or without decreased ejection fraction) 1

Hepatic Monitoring

• ALT and AST every 2 weeks during first month
• Monthly thereafter and as clinically indicated
• More frequent monitoring if transaminase elevations occur 1

QT Interval Monitoring

• Baseline ECG and electrolytes
• Periodic ECG monitoring during treatment, especially in patients with:
  • Pre-existing QT prolongation
  • Concomitant QT-prolonging medications
  • Electrolyte abnormalities
  • Congestive heart failure
  • Bradyarrhythmias 1

Metabolic Monitoring

• Serum uric acid at baseline and periodically during treatment
• Monitor for signs/symptoms of hyperuricemia (joint pain, gout flares) 1

CNS Monitoring

• Assess for cognitive impairment, mood changes, dizziness, sleep disturbances at each visit
• These are common adverse effects requiring dose modification 1

Dose Modifications for Adverse Events

Congestive Heart Failure

• Grade 2 CHF: Withhold until recovery to Grade ≤1, then resume at reduced dose (400 mg daily in adults)
• Grade 3 CHF: Withhold until recovery to Grade ≤1, then resume at 200 mg daily
• Grade 4 CHF or recurrent Grade 3: Permanently discontinue 1

CNS Effects (cognitive impairment, mood disorders, dizziness)

• Grade 2: Withhold until recovery to Grade ≤1, then resume at same dose
• Grade 3: Withhold until recovery to Grade ≤1, then resume at reduced dose (400 mg daily)
• Grade 4 or recurrent Grade 3: Permanently discontinue 1

Hepatotoxicity

• ALT/AST >3-5× ULN: Withhold until recovery to baseline or ≤3× ULN, then resume at reduced dose (400 mg daily)
• ALT/AST >5-10× ULN: Withhold until recovery, then resume at 200 mg daily
• ALT/AST >10× ULN or >3× ULN with total bilirubin >2× ULN: Permanently discontinue 1

QT Prolongation

• QTc 481-500 ms: Withhold until QTc ≤480 ms, then resume at reduced dose (400 mg daily)
• QTc >500 ms: Withhold until QTc ≤480 ms, then resume at 200 mg daily
• QTc >500 ms with torsades de pointes, polymorphic ventricular tachycardia, or serious arrhythmia: Permanently discontinue 1

Hyperuricemia

• Initiate urate-lowering therapy (allopurinol or febuxostat) as clinically indicated
• Withhold entrectinib for symptomatic hyperuricemia until symptoms resolve
• Resume at same dose if Grade 1-2; resume at reduced dose if Grade 3 1

Special Precautions

Uncontrolled Hypertension

While not explicitly contraindicated, optimize blood pressure control before initiating entrectinib given the cardiac toxicity profile and QT prolongation risk. Monitor blood pressure regularly during treatment.

CNS Disorders

Exercise caution in patients with pre-existing CNS disorders (seizures, cognitive impairment, psychiatric conditions). Entrectinib causes CNS adverse reactions in a substantial proportion of patients (cognitive impairment, mood disorders, dizziness occur commonly) 1. Consider baseline neuropsychological assessment in high-risk patients.

Pregnancy

Entrectinib can cause fetal harm. Advise females of reproductive potential to:

• Use effective non-hormonal contraception during treatment and for 5 weeks after final dose
• Avoid pregnancy during treatment
• Inform prescriber immediately if pregnancy occurs 1

Verify pregnancy status before initiating treatment in females of reproductive potential.

Clinical Efficacy Context

Entrectinib demonstrates robust efficacy in both indications:

ROS1-positive NSCLC: 77% objective response rate in first-line treatment, with 55% intracranial response rate in patients with baseline CNS metastases 2. However, entrectinib is more toxic than crizotinib (34% Grade 3-4 adverse events vs. no Grade 4+ events with crizotinib), though it offers superior CNS penetration 2.

NTRK fusion-positive solid tumors: 57-64.5% objective response rate across tumor types, with 60-63% intracranial response rate in patients with CNS metastases 2, 3. Median duration of response is 10 months 3.

The NCCN guidelines recommend entrectinib as a preferred first-line option for both ROS1-positive NSCLC and NTRK fusion-positive tumors 2, alongside alternatives like crizotinib/repotrectinib (for ROS1) and larotrectinib (for NTRK).

Critical Pitfalls to Avoid

1. Do not skip baseline cardiac assessment - CHF is a serious toxicity requiring LVEF monitoring
2. Do not overlook drug interactions - CYP3A inhibitors/inducers significantly alter entrectinib exposure
3. Do not dismiss early CNS symptoms - cognitive changes and dizziness are common and require dose modification
4. Do not use oral pellets for enteral tube administration - only capsules prepared as suspension are appropriate 1
5. Do not ignore QT prolongation - 3.1% of patients develop QTc >60 ms prolongation; monitor ECG regularly 1
6. Do not delay hepatic monitoring - check ALT/AST every 2 weeks for the first month